Institution
German Red Cross
Healthcare•Berlin, Germany•
About: German Red Cross is a healthcare organization based out in Berlin, Germany. It is known for research contribution in the topics: Transplantation & Mesenchymal stem cell. The organization has 653 authors who have published 1146 publications receiving 40111 citations. The organization is also known as: Deutsches Rotes Kreuz & DRK.
Topics: Transplantation, Mesenchymal stem cell, Population, Stem cell, Antigen
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The Elecsys anti-SARS-CoV-2 immunoassay (Roche Diagnostics) as mentioned in this paper was used for the in vitro qualitative detection of antibodies to severe acute respiratory syndrome coronavirus (SARS)-2.
Abstract: We performed a multicentre evaluation of the Elecsys® Anti-SARS-CoV-2 immunoassay (Roche Diagnostics), an assay utilising a recombinant protein representing the nucleocapsid (N) antigen, for the in vitro qualitative detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Specificity was evaluated using serum/plasma samples from blood donors and routine diagnostic specimens collected before September 2019 (i.e., presumed negative for SARS-CoV-2-specific antibodies); sensitivity was evaluated using samples from patients with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection. Point estimates and 95% confidence intervals (CIs) were calculated. Method comparison was performed versus commercially available assays. Overall specificity for the Elecsys Anti-SARS-CoV-2 immunoassay (n = 9575) was 99.85% (95% CI 99.75–99.92): blood donors (n = 6714; 99.82%), routine diagnostic specimens (n = 2861; 99.93%), pregnant women (n = 2256; 99.91%), paediatric samples (n = 205; 100.00%). The Elecsys Anti-SARS-CoV-2 immunoassay demonstrated significantly higher specificity versus LIAISON SARS-CoV-2 S1/S2 IgG (99.71% vs. 98.48%), EUROIMMUN Anti-SARS-CoV-2 IgG (100.00% vs. 94.87%), ADVIA Centaur SARS-CoV-2 Total (100.00% vs. 87.32%) and iFlash SARS-CoV-2 IgM (100.00% vs. 99.58%) assays, and comparable specificity to ARCHITECT SARS-CoV-2 IgG (99.75% vs. 99.65%) and iFlash SARS-CoV-2 IgG (100.00% vs. 100.00%) assays. Overall sensitivity for Elecsys Anti-SARS-CoV-2 immunoassay samples drawn at least 14 days post-PCR confirmation (n = 219) was 93.61% (95% CI 89.51–96.46). No statistically significant differences in sensitivity were observed between the Elecsys Anti-SARS-CoV-2 immunoassay versus EUROIMMUN Anti-SARS-CoV-2 IgG (90.32% vs. 95.16%) and ARCHITECT SARS-CoV-2 IgG (84.81% vs. 87.34%) assays. The Elecsys Anti-SARS-CoV-2 immunoassay showed significantly lower sensitivity versus ADVIA Centaur SARS-CoV-2 Total (85.19% vs. 95.06%) and iFlash SARS-CoV-2 IgG (86.25% vs. 93.75%) assays, but significantly higher sensitivity versus the iFlash SARS-CoV-2 IgM assay (86.25% vs. 33.75%). The Elecsys Anti-SARS-CoV-2 immunoassay demonstrated very high specificity and high sensitivity in samples collected at least 14 days post-PCR confirmation of SARS-CoV-2 infection, supporting its use to aid in determination of previous exposure to SARS-CoV-2.
11 citations
••
TL;DR: In this paper, the efficacy of neutralizing antibody containing high-dose COVID-19 convalescent plasma (CCP) was evaluated in hospitalized adults requiring respiratory support or intensive care treatment.
Abstract: RationaleCOVID-19 convalescent plasma (CCP) has been considered a treatment option in COVID-19. ObjectivesTo assess the efficacy of neutralizing antibody containing high-dose CCP in hospitalized adults with COVID-19 requiring respiratory support or intensive care treatment. MethodsPatients (n=105) were randomized 1:1 to either receive standard treatment and 3 units of CCP or standard treatment alone. Control group patients with progress on day 14 could cross over to the CCP group. Primary outcome was a dichotomous composite outcome of survival and no longer fulfilling criteria for severe COVID-19 on day 21. The trial is registered: clinicaltrials.gov #NCT04433910. Measurements and main resultsThe primary outcome occurred in 43.4% of patients in the CCP and 32.7% in the control group (p=0.32). The median time to clinical improvement was 26 days (IQR 15-not reached (n.r.)) in the CCP group and 66 days (IQR 13-n.r.) in the control group (p=0.27). Median time to discharge from hospital was 31 days (IQR 16-n.r.) in the CCP and 51 days (IQR 20-n.r.) in the control group (p=0.24). In the subgroup that received a higher cumulative amount of neutralizing antibodies the primary outcome occurred in 56.0% (versus 32.1%), with a shorter interval to clinical improvement, shorter time to hospital discharge and better survival compared to the control group. ConclusionCCP added to standard treatment did not result in a significant difference in the primary and secondary outcomes. A pre-defined subgroup analysis showed a significant benefit for CCP among those who received a larger amount of neutralizing antibodies.
11 citations
••
TL;DR: The HIV-1 Gag subtype panel has a broad diversity and proved useful for a standardised evaluation of the detection limit and breadth of subtype detection of p24 antigen-detecting tests.
Abstract: Background: Detection of HIV-1 p24 antigen permits early identification of primary HIV infection and timely intervention to limit further spread of the infection. Principally, HIV screening should equally detect all viral variants, but reagents for a standardised test evaluation are limited. Therefore, we aimed to create an inexhaustible panel of diverse HIV-1 p24 antigens. Methods: We generated a panel of 43 recombinantly expressed virus-like particles (VLPs), containing the structural Gag proteins of HIV-1 subtypes A-H and circulating recombinant forms (CRF) CRF01_AE, CRF02_AG, CRF12_BF, CRF20_BG and group O. Eleven 4 th generation antigen/antibody tests and five antigen-only tests were evaluated for their ability to detect VLPs diluted in human plasma to p24 concentrations equivalent to 50, 10 and 2 IU/ml of the WHO p24 standard. Three tests were also evaluated for their ability to detect p24 after heat-denaturation for immune-complex disruption, a pre-requisite for ultrasensitive p24 detection. Results: Our VLP panel exhibited an average intra-clade p24 diversity of 6.7%. Among the 4 th generation tests, the Abbott Architect and Siemens Enzygnost Integral 4 had the highest sensitivity of 97.7% and 93%, respectively. Alere Determine Combo and BioRad Access were least sensitive with 10.1% and 40.3%, respectively. Antigen-only tests were slightly more sensitive than combination tests. Almost all tests detected the WHO HIV-1 p24 standard at a concentration of 2 IU/ml, but their ability to detect this input for different subtypes varied greatly. Heat-treatment lowered overall detectability of HIV-1 p24 in two of the three tests, but only few VLPs had a more than 3-fold loss in p24 detection. Conclusions: The HIV-1 Gag subtype panel has a broad diversity and proved useful for a standardised evaluation of the detection limit and breadth of subtype detection of p24 antigen-detecting tests. Several tests exhibited problems, particularly with non-B subtypes.
11 citations
••
TL;DR: The presence of LOH in EDA2R, TAF9B, and CYSLTR1 genes is associated with metastasis-free survival in breast cancer patients, indicating their potential value as prognostic markers.
Abstract: One of the factors providing the diversity and heterogeneity of malignant tumors, particularly breast cancer, are genetic variations, due to gene polymorphism, and, especially, the phenomenon of loss of heterozygosity (LOH). It has been shown that LOH in some genes could be a good prognostic marker. AIM To perform genome-wide study on LOH in association with metastasis-free survival in breast cancer. MATERIALS AND METHODS The study involved 68 patients with breast cancer. LOH status was detected by microarray analysis, using a high density DNA-chip CytoScanTM HD Array (Affymetrix, USA). The Chromosome Analysis Suite 3.1 (Affymetrix, USA) software was used for result processing. RESULTS 13,815 genes were examined, in order to detect LOH. The frequency of LOH varied from 0% to 63%. The association analysis identified four genes: EDA2R, PGK1, TAF9B and CYSLTR1 that demonstrated the presence of LOH associated with metastasis-free survival (log-rank test, p < 0.03). CONCLUSIONS The presence of LOH in EDA2R, TAF9B, and CYSLTR1 genes is associated with metastasis-free survival in breast cancer patients, indicating their potential value as prognostic markers.
11 citations
••
TL;DR: Describing data on the distribution and characteristics of psychogenic and functional breathing disorders in a specialized outpatient department for paediatric allergology and pneumology was delivered, with Habit cough being the most common diagnosis.
Abstract: To the Editors, Psychogenic and functional breathing disorders represent a variety of disease patterns, which can be allocated to the ICD-10 classification of ‘Somatoform autonomic dysfunction of the respiratory tract’ (F45.33). These clinical entities are still underdiagnosed although they represent important differential diagnoses to organic airway diseases such as bronchial asthma (1–3). Furthermore, both psychogenic and functional breathing disorders as well as organic disease may coincide in one patient (4, 5). Examples of psychogenic breathing disorders include sighing dyspnoea, hyperventilation and panic attacks accompanied with dyspnoea, while functional breathing is attributed to entities such as vocal cord dysfunction (VCD). Visible and audible paradoxical vocal cord movements with a psychological background characterize the latter. Very little epidemiological data are available for these clinical entities (6). To our knowledge, there is no information about population-based figures. Aim of this pilot study was to deliver descriptive data on the distribution and characteristics of psychogenic and functional breathing disorders in a specialized outpatient department for paediatric allergology and pneumology. We recruited 132 children and adolescents, consecutively seen in the outpatient department between October 2007 and June 2011. The only inclusion criterion was the physicianbased diagnosis with ICD-10 F45.33 (7, 8). Seventy-four (56%) were females, 58 (44%) males and median age was 10.5 yr (ranging from 3 to 18 yr). The Table 1 shows the percentages of the eight diagnosed clinical entities. Habit cough was the most common diagnosis. Although vocal cord dysfunction has been known for years and many cases have been published, it is rare compared to the other entities. In 15 (11%) patients, a combination of two or more of the entities (e.g. habit cough plus tic-like disorder or sighing dyspnoea plus hyperventilation) was diagnosed. Age distribution showed an implied tendency towards two peaks: one between 7 and 11 yr with a predominance in boys, and a second peak between 7 and 17 in favour of girls (Fig. 1). Habit cough seems to be more common in younger boys and pure psychogenic breathings disorders more common in older girls. Trigger factors were mentioned by 40 (30%) of patients. Physical exercise was the most common reported trigger factor
11 citations
Authors
Showing all 658 results
Name | H-index | Papers | Citations |
---|---|---|---|
Johannes Oldenburg | 72 | 583 | 18790 |
Bodo Niggemann | 71 | 279 | 19475 |
Norbert Weissmann | 71 | 384 | 21187 |
Hubert Schrezenmeier | 69 | 360 | 16215 |
Triantafyllos Chavakis | 65 | 242 | 13247 |
Klaus Schwarz | 58 | 209 | 13407 |
Willy A. Flegel | 50 | 233 | 6742 |
Rainer M. Bohle | 49 | 235 | 6923 |
Torsten Tonn | 48 | 151 | 11328 |
Daniel Ricklin | 46 | 144 | 10713 |
Erhard Seifried | 44 | 254 | 7967 |
Pamela S. Becker | 42 | 257 | 6256 |
Karen Bieback | 41 | 135 | 10010 |
Halvard Bonig | 41 | 216 | 4828 |
Julia Kzhyshkowska | 40 | 126 | 5963 |